| Title |
Entry time effects and follow-on drug competition
|
|---|---|
| Published in |
HEPAC Health Economics in Prevention and Care, December 2014
|
| DOI | 10.1007/s10198-014-0654-9 |
| Pubmed ID | |
| Authors |
Luiz Flavio Andrade, Catherine Sermet, Sylvain Pichetti |
| Abstract |
Pharmaceutical firms have been criticized for concentrating efforts of R&D on the so-called me-too or follow-on drugs. There have been many comments for and against the dissemination of these incremental innovations but few papers have broached the subject from an econometric point of view, possibly because identification of me-too or follow-on drugs is not so obvious. This paper focuses on the impact of entry order on follow-on drug competition in the French market between the years 2001 and 2007. More precisely, this study examines the effects on market share of first entrants in the follow-on drug market and how this possible competitive advantage changes over time. First results are coherent with theoretical microeconomic issues concerning the importance of being first. We find evidence that first movers in the follow-on drug market have the ability to capture and maintain greater market share for a long period of time. The hierarchical market position of follow-on drugs does not seem to be affected by generic drug emergence. From a dynamic perspective, our analysis shows that market share is positively correlated with the ability of follow-on drugs to set prices higher than the average follow-on drug prices in a specific therapeutic class, which means that market power remains considerably important for first movers. Moreover, we found that the optimum level of innovation to maximize market share is the highest one. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 56 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 2 | 4% |
| Unknown | 54 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 8 | 14% |
| Student > Master | 8 | 14% |
| Researcher | 7 | 13% |
| Student > Doctoral Student | 6 | 11% |
| Other | 4 | 7% |
| Other | 9 | 16% |
| Unknown | 14 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Economics, Econometrics and Finance | 9 | 16% |
| Business, Management and Accounting | 9 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 11% |
| Medicine and Dentistry | 5 | 9% |
| Social Sciences | 5 | 9% |
| Other | 6 | 11% |
| Unknown | 16 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 December 2014.
All research outputs
#20,657,128
of 25,374,917 outputs
Outputs from HEPAC Health Economics in Prevention and Care
#1,039
of 1,303 outputs
Outputs of similar age
#269,813
of 363,219 outputs
Outputs of similar age from HEPAC Health Economics in Prevention and Care
#23
of 25 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,303 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one is in the 7th percentile – i.e., 7% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 363,219 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one is in the 4th percentile – i.e., 4% of its contemporaries scored the same or lower than it.